News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Serono International S.A. (SRA) Says Cancer Drug Fails To Meet Goals


10/2/2006 9:14:19 AM

ZURICH, Oct 2 (Reuters) - Swiss biotech firm Serono (SEO.VX: Quote, Profile, Research) said on Monday that two Phase II studies using adecatumumab (MT201) as a treatment for metastatic breast cancer and prostate cancer failed to meet their goals but the drug may have some benefits.

>>> Discuss This Story


Read at Reuters
Read at Bloomberg
Read at New Ratings
Read at AFX Press

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES